{"id": "1346570417490849793", "creation": 1609882380.0, "user_id": "18026170", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 1, "reply_count": 0, "like_count": 2, "quote_count": 0}}, "text": "#CRDMO @LakePharma to manufacture #AkstonBio\u2019s #COVID19 #vaccine AKS-452 for Ph1/2 #ClinicalTrials\n\nShelf-stable Fc fusion vs #SARSCoV2 #spike #RBD designed to induce mixed Th1/Th2 #immune response\n\nhttps://t.co/zsqRHIpt7q\n#InfectiousDiseases #GlobalHealth @NormanBirnbach https://t.co/9IIZVqTW4Q", "first_save": 1634559108.199414, "hashtags": ["#CRDMO", "#AKSTONBIO", "#COVID19", "#VACCINE", "#CLINICALTRIALS", "#SARSCOV2", "#SPIKE", "#RBD", "#IMMUNE", "#INFECTIOUSDISEASES", "#GLOBALHEALTH"]}